Medicus Pharma Ltd. Common Stock
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Raza Bokhari
- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 300 Conshohocken State Rd. Suite 200 W. Conshohocken Canada 19428
- IPO Date
- Nov 15, 2024
- CIK
- 0001997296
- Website
- medicuspharma.com
- Similar Companies
- Business
- Medicus Pharma Ltd. (NASDAQ:MDCX) is a biotech and life sciences company that focuses on accelerating the clinical development and commercialization of novel and disruptive therapeutic assets through acquisitions, partnerships and targeted investments. The company develops SkinJect, a patented dissolvable doxorubicin-containing microneedle array (D-MNA) as a non-invasive treatment for basal cell carcinoma and other non-melanoma skin cancers via ongoing Phase 2 trials including SKNJCT-003 in the United States and Europe and SKNJCT-004 in the United Arab Emirates; through its August 2025 acquisition of Antev Limited, it now advances Teverelix trifluoroacetate, a next-generation long-acting GnRH antagonist formulated as a microcrystalline suspension for sustained release every six weeks to treat acute urinary retention relapse in enlarged prostate patients and advanced prostate cancer in high cardiovascular-risk individuals, with FDA-approved Phase 2b study designs for 390 and 40 patients respectively. Medicus Pharma operates across three continents with clinical activities in the United States, United Kingdom, United Arab Emirates and Europe; founded in 2008, it maintains headquarters in Conshohocken, Pennsylvania, with prior Canadian operations in Toronto. Recent developments include the September 2025 acquisition of 98.6% of Antev for $2.97 million in cash plus 1.6 million shares and up to $65 million in contingent milestone payments tied to FDA approvals, adding Teverelix and industry veteran Patrick J. Mahaffy to its board; a strategic October 2025 collaboration with the Gorlin Syndrome Alliance to pursue FDA Expanded Access for SkinJect in patients with multiple recurrent basal cell carcinomas; an August 2025 non-binding memorandum of understanding with Helix Nanotechnologies to explore co-development of thermostable mRNA infectious disease vaccines combining microneedle delivery; positive FDA Type C meeting feedback in September 2025 supporting the 505(b)(2) pathway for SkinJect; full UK regulatory approvals in November 2025 to expand SKNJCT-003; and first patient dosing in SKNJCT-004. Subsidiaries include SkinJect Inc. and Antev Limited, with operations targeting unmet needs in oncology and urology for improved patient safety, efficacy and compliance.
Medicus Pharma CEO details Teverelix progress – ICYMI
Medicus Pharma CEO details Teverelix progress – ICYMI
Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval
Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026
Medicus Pharma advances Teverelix in prostate cancer - ICYMI
Medicus Pharma advances Teverelix in prostate cancer - ICYMI
Medicus Pharma seeks rare pediatric disease tag for SkinJect in Gorlin Syndrome
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
Medicus Pharma files IND for genomics-enabled endometriosis trial in UAE
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
Medicus Pharma files IND for genomics-enabled endometriosis trial in UAE
Medicus Pharma submits EU clinical trial modification for prostate cancer drug Teverelix
Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
Medicus Pharma advances SkinJect for Gorlin syndrome – ICYMI
Medicus Pharma advances SkinJect for Gorlin syndrome – ICYMI
Solidion Technology shares surge after company unveils extreme-climate battery technology
SpaceX IPO: Just how high can the rocket fly?
FTSE 100 Live: Stocks heading lower despite oil falling on Israel deal